Tempus (IPO)

Funding Details
Awarder
Inbox
Date Award
June 12, 2024
Vertical
AI health tech
Funding URL
View Funding Page
Valuation
$8,100,000

Company Info
Founding Year
2015
Traction
Tempus has shown strong revenue growth, reaching $531 million in 2023. The company is focused on genomic testing and data analysis in the healthcare sector.
Revenue Amount
$531,000,000
Organizations Involved
NEA, Revolution Growth, T. Rowe Price, Novo Holdings, Franklin Templeton, Baillie Gifford, SoftBank
Founders
Eric Lefkofsky
Company Description
Tempus is a genomic testing and data analysis company founded by Eric Lefkofsky in 2015. The company focuses on applying technology to cancer care to help physicians make data-driven decisions. Tempus has shown significant revenue growth, reaching $531 million in 2023, with a focus on genomic testing and data analysis in the healthcare sector.
Market
Healthcare
Location
Chicago, IL, US
Coinvestors
NEA, Revolution Growth, T. Rowe Price, Novo Holdings, Franklin Templeton, Baillie Gifford, SoftBank

Links
Back to Home Back to AI health tech Deals View Funding Announcement